Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Buying opportunity - Market maker out of business -- Ignore unavailable to you. Want to Upgrade?

To: grover who wrote (20)	1/11/1998 11:09:00 AM
From: Master (Hijacked)	Read Replies (1) \| Respond to of 472

FLEM could go up a lot. FLEM will make all its money off collaborative agreements with major pharmaceutical companies based on its products. It already has 2 products with patent-pending and 2 development agreements with major pharmaceutical companies inked. The latest 10Q shows enough cash to go 24 months. That means investors will be fighting over the existing tiny float for 2 years with no dilution as the licensing agreements pour in- FLEM is looking at 50 drugs it can license its patent-pending drug delivery process. SLHO signed just 1 licencing agreement with Texaco based on their patented system and the stock went from $5-$70 last year. RNTK looks like it will do the same this year. So there are big possibilities in licensing agreements for FLEM- you can reap the rewards of 15 years of hard work and STEAL it at $1.62- just 20% what people paid 1 month ago. FLEM is a sucessful consulting company thats been open since 1982. The principals are PHD's and nobody's paid less than $5 for the stock except for the MOPA related crash. All FLEM does is license their product and get checks in the mail- they don't have to go through the cost and expense of the manufacturing process-its all profit. Thats why at $1.62 its a STEAL... people might be fighting over this stock at $20, $30, or $60 this year if even 1 licensing agreement is announced. Along with VCLL with their special paints and ISON with their monopoly of depleted zinc writing long-term sales contracts with all the nuclear power plants worldwide, FLEM licencing its 2 medical devices will reap exponential returns from the MOPA crash. And since all 3 stocks have tiny floats, the returns will be quick. From EDGAR filings: Company Background Flemington Pharmaceutical Corporation, a New Jersey corporation (the "Company"), is engaged in the development of novel application drug delivery systems for presently marketed prescription and over-the-counter ("OTC") drugs. The Company's patent-pending delivery systems are lingual sprays and soft gelatin bite capsules, enabling drug absorption through the oral mucosa, and more rapid absorption into the bloodstream than presently available oral delivery systems. The Company's proprietary oral dosage delivery systems enhance and greatly accelerate the onset of the therapeutic benefits which the drugs are intended to produce. The Company refers to its delivery systems as Immediate-Immediate Release I(2)R(TM) because its delivery systems are designed to provide therapeutic benefits within minutes of administration. The Company's development efforts for its novel drug delivery systems are concentrated on drugs which are already available and proven in the marketplace. In addition to increasing bioavailability by avoiding metabolism by the liver before entry into the bloodstream, the Company believes that its proprietary delivery systems offer the following significant advantages: 4 (i) improved drug safety profile by reducing the required dosage, including possible reduction of side-effects; (ii) improved dosage reliability; (iii) allowing medication to be taken without water; and (iv) improved patient convenience and compliance. The Company has initially identified approximately fifty (50) presently marketed drugs that meet the Company's criteria for its drug delivery systems. The Company will concentrate its product development activities on those pharmaceuticals with significant prescription or OTC sales. The Company believes that applying a novel application delivery system to existing drugs involves less cost, time and risk than developing and commercializing a new chemical entity. The Company believes that there is significant opportunity to combine its delivery systems with existing pharmaceuticals to expand the market for an existing drug, differentiate a product from a generic or brand name competition, and possibly create new markets. In light of the material expense and delays associated with independently developing and obtaining approval of pharmaceutical products, the Company will only continue to develop such products through collaborative arrangements with major pharmaceutical companies, which will fund that development. To date, the Company has signed two such development agreements with major pharmaceutical companies. The Company was incorporated in New Jersey in 1982 under the name Pharmaconsult, Inc. and in 1992 the Company's name was changed to Flemington Pharmaceutical Corporation. Since its inception, the Company has been a consultant to the pharmaceutical industry, focusing on product development activities of various European pharmaceutical companies, and since 1992 has used its consulting revenues to fund its own product development activities. The Company's recent focus on developing its own products evolved naturally out of its consulting experience for other pharmaceutical companies. Substantially all of the Company's revenues have been derived from its consulting activities. The Company's business address is 43 Emery Avenue, Flemington, New Jersey 08822, and its telephone number is (908) 782-3431.